TetraLogic Pharmaceuticals Corp., a Malvern clinical-stage biopharmaceutical company, has elected Mary Ann Gray and Michael D. Kishbauch as Class I directors. Gray is president of Gray Strategic Advisors L.L.C. and was a senior analyst and portfolio manager for the Federated Kaufmann Fund. Kishbauch served as chief executive officer and president of Achillion Pharmaceuticals Inc.